Selecta Biosciences Receives Exclusive Rights To Peanut Allergy And Celiac Disease Programs

WATERTOWN, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced that it is receiving worldwide rights to intellectual property, data and materials generated through a discovery collaboration initiated and funded by Sanofi for the development of product candidates to treat peanut allergy and celiac disease. This follows Sanofi's strategic review of its R&D portfolio, which resulted in a decision to exit this collaboration with Selecta. The transition of these discovery programs is not expected to have a material impact on Selecta's cash runway.

Selecta continues to focus its core activities on the development of biologic therapies that leverage its immune tolerance Synthetic Vaccine Particles (SVP™) platform to prevent unwanted immunogenicity. This is exemplified by the company's lead Phase 2 clinical program, SEL-212, for the treatment of chronic refractory and tophaceous gout, as well as by its development of proprietary gene therapy product candidates and technologies. As was the case with the Sanofi collaboration, the company intends to partner or out-license its SVP technology for indications that are outside its core areas of focus.

Selecta and Sanofi entered into a license and research collaboration agreement focused on peanut allergy in November 2012. As a result of the research performed under this collaboration, the companies developed a research vaccine candidate that encapsulates peanut extract and an immune stimulating adjuvant using Selecta's SVP technology. This research candidate has demonstrated rapid onset and long duration of therapeutic activity in animal models of allergy. In May 2015, Sanofi exercised an option to extend the agreement to celiac disease. Through this program, the companies developed an approach to use gluten with Selecta's SVP technology. Selecta plans to evaluate strategic opportunities to continue advancing these non-core programs.